Evidence map›Paper›PMID 34747035›Full record

ReviewImmunological reviews2022

What sequencing technologies can teach us about innate immunity.

Mays Mohammed Salih, Susan Carpenter

Open access · greenAbstract readReview
In one paragraph

Review in Immunological reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mays Mohammed SalihDepartment of Molecular Cell and Developmental Biology, University of California Santa Cruz, Santa Cruz, California, USA.ORCID 0000-0002-6687-3483
Susan CarpenterDepartment of Molecular Cell and Developmental Biology, University of California Santa Cruz, Santa Cruz, California, USA.ORCID 0000-0002-5600-5404
University of California, Santa Cruz · US

Funding

Enhanced Surveillance-Newly Vaccine Preventable DiseasesU01IP000017 · IP · UNIVERSITY OF ROCHESTER · PI SZILAGYI, PETER G · 2004 to 2010
$3.8M
High throughput functional characterization of lncRNAs in macrophage biologyR35GM137801 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI CARPENTER, SUSAN · 2020 to 2024
$2.2M
Determining the conserved molecular mechanisms contributing to inflammation during SepsisR01AI148413 · NIAID · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI CARPENTER, SUSAN · 2020 to 2024
$1.9M
NCIRD CDC HHS U01 IP000017NIAID NIH HHS R01 AI148413NIGMS NIH HHS R35 GM137801
6 · The paper itself

Abstract

For years, we have taken a reductionist approach to understanding gene regulation through the study of one gene in one cell at a time. While this approach has been fruitful it is laborious and fails to provide a global picture of what is occurring in complex situations involving tightly coordinated immune responses. The emergence of whole-genome techniques provides a system-level view of a response and can provide a plethora of information on events occurring in a cell from gene expression changes to splicing changes and chemical modifications. As with any technology, this often results in more questions than answers, but this wealth of knowledge is providing us with an unprecedented view of what occurs inside our cells during an immune response. In this review, we will discuss the current RNA-sequencing technologies and what they are helping us learn about the innate immune system.

Indexed as

Gene Expression RegulationImmunity, InnateHigh-Throughput Nucleotide SequencingHumansImmune SystemTechnologyCRISPRinnate immunitylong non-coding RNAslong-read sequencingnext-generation sequencingRNA modifications

Identifiers

PMID34747035
PMCPMC8865538
OpenAlexW3214659104

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.